{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:47:44Z","timestamp":1782182864896,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesopancreas excision has emerged as a critical component of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC), potentially improving oncological outcomes. However, comprehensive data on recurrence patterns following mesopancreas excision remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze recurrence patterns in patients with PDAC who underwent pancreaticoduodenectomy with mesopancreas excision at a tertiary care center in Egypt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-arm, single-center, retrospective descriptive cohort study with prospective follow-up included 86 patients with PDAC who underwent pancreaticoduodenectomy with complete mesopancreas excision at Liver and GIT Hospital, Minia University, between February 2018 and February 2024. Patients were followed for a minimum of 24 months, with data collection concluding in February 2026. Data collected included demographics, tumor characteristics, surgical outcomes, pathological findings, and recurrence patterns. The primary outcome was disease recurrence; secondary outcomes included recurrence-free survival (RFS), overall survival (OS), and patterns of recurrence distribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 86 patients (mean age 58.4\u2009\u00b1\u20099.2 years, 61.6% male), R0 resection was achieved in 73 patients (84.9%). During follow-up, 52 patients (60.5%) developed recurrence at a median of 11.3 months. Local recurrence occurred in 18 patients (34.6%), distant metastases in 21 patients (40.4%), and combined recurrence in 13 patients (25.0%). The liver was the most common site of distant recurrence, involved in 42.3% of all recurrent cases, followed by lungs (23.1%) and peritoneum (19.2%). Median RFS was 13.2 months (95% CI: 10.8\u201315.6), and median OS was 18.7 months (95% CI: 16.3\u201321.1). Lymph node positivity (HR 2.34,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), poor differentiation (HR 1.89,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012), and elevated CA19-9 (HR 1.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028) were independent predictors of recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite complete mesopancreas excision, PDAC demonstrates high recurrence rates with a predominant distant metastatic pattern. Early systemic therapy and intensive surveillance protocols may be warranted for high-risk patients. This study describes the recurrence patterns following complete mesopancreas excision; however, due to the absence of a concurrent control group and the exclusion of patients requiring vascular resection\/reconstruction, any superiority in the observed R0 resection rate cannot be directly attributed to the surgical technique itself, and prospective randomized controlled trials remain necessary to establish the oncological benefit of complete mesopancreas excision over standard pancreaticoduodenectomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04459-4","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:34:02Z","timestamp":1782088442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mesopancreas excision in pancreatic ductal adenocarcinoma: recurrence patterns \u2014 a single-arm descriptive study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-7561","authenticated-orcid":false,"given":"Saleh Khairy","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrhman Gamal","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tantawi Abdelnaeem","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina Makram","family":"Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Sadek","family":"Farahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Thabet","family":"Boushra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Mosa","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabeh Khairy","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"1","key":"4459_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"key":"4459_CR2","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. https:\/\/doi.org\/10.1038\/nrdp.2016.22.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"4459_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039\u201349. https:\/\/doi.org\/10.1056\/NEJMra1404198.","journal-title":"N Engl J Med"},{"issue":"21","key":"4459_CR4","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1200\/JCO.2016.67.5553","volume":"34","author":"AA Khorana","year":"2016","unstructured":"Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541\u201356. https:\/\/doi.org\/10.1200\/JCO.2016.67.5553.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4459_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","volume":"16","author":"O Strobel","year":"2019","unstructured":"Strobel O, Neoptolemos J, J\u00e4ger D, B\u00fcchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11\u201326. https:\/\/doi.org\/10.1038\/s41571-018-0112-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"4459_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1477-7819-5-44","volume":"5","author":"I Gockel","year":"2007","unstructured":"Gockel I, Domeyer M, Wolloscheck T, Konerding MA, Junginger T. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World J Surg Oncol. 2007;5:44. https:\/\/doi.org\/10.1186\/1477-7819-5-44.","journal-title":"World J Surg Oncol"},{"issue":"12","key":"4459_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.ejso.2013.10.012","volume":"39","author":"N Peparini","year":"2013","unstructured":"Peparini N, Chirletti P. Mesopancreas: a boundless structure, namely R1 risk in pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol. 2013;39(12):1303\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.012.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"4459_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejso.2011.12.015","volume":"38","author":"M Adham","year":"2012","unstructured":"Adham M, Singhirunnusorn J. Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors. Eur J Surg Oncol. 2012;38(4):340\u20135. https:\/\/doi.org\/10.1016\/j.ejso.2011.12.015.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"4459_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12957-024-03495-2","volume":"22","author":"LFL da Silva","year":"2024","unstructured":"da Silva LFL, Belotto M, de Almeida LFC, Samuel J, Pereira LH, Albagli RO, de Araujo MS, Ramia JM. Radicality and safety of total mesopancreatic excision in pancreatoduodenectomy: a systematic review and meta-analysis. World J Surg Oncol. 2024;22(1):217. https:\/\/doi.org\/10.1186\/s12957-024-03495-2.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"4459_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/SLA.0000000000001065","volume":"262","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J, et al. Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach. Ann Surg. 2015;262(6):1092\u2013101. https:\/\/doi.org\/10.1097\/SLA.0000000000001065.","journal-title":"Ann Surg"},{"issue":"3","key":"4459_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s10353-024-00830-5","volume":"56","author":"T Hank","year":"2024","unstructured":"Hank T, Leonhardt CS, Klaiber U, Strobel O. Intraoperative strategies and techniques to achieve surgical radicality in pancreatic cancer. Eur Surg. 2024;56(3):86\u201392. https:\/\/doi.org\/10.1007\/s10353-024-00830-5.","journal-title":"Eur Surg"},{"issue":"5","key":"4459_CR12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018;267(5):936\u201345. https:\/\/doi.org\/10.1097\/SLA.0000000000002234.","journal-title":"Ann Surg"},{"issue":"11","key":"4459_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, et al. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg. 2019;154(11):1038\u201348. https:\/\/doi.org\/10.1001\/jamasurg.2019.3337.","journal-title":"JAMA Surg"},{"key":"4459_CR14","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1186\/s12885-024-12955-7","volume":"24","author":"N Rashad","year":"2024","unstructured":"Rashad N, Gouda A, Sabra E, et al. Early Onset Pancreatic Adenocarcinoma (EOPAC): presentation, clinical course and treatment outcomes in comparison to Average Onset Pancreatic Adenocarcinoma (AOPAC): a retrospective cohort study. BMC Cancer. 2024;24:1289. https:\/\/doi.org\/10.1186\/s12885-024-12955-7.","journal-title":"BMC Cancer"},{"issue":"12","key":"4459_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","volume":"4","author":"GBD 2017 Pancreatic Cancer Collaborators","year":"2019","unstructured":"GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934\u201347. https:\/\/doi.org\/10.1016\/S2468-1253(19)30347-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4459_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4459_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"issue":"2","key":"4459_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4459_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3978\/j.issn.2078-6891.2011.021","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19\u2009\u2013\u20099 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105\u201319. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2011.021.","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"4459_CR20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s11605-009-0919-2","volume":"13","author":"H Riediger","year":"2009","unstructured":"Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13(7):1337\u201344. https:\/\/doi.org\/10.1007\/s11605-009-0919-2.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"4459_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tranon.2018.08.017","volume":"12","author":"GC Mattiucci","year":"2019","unstructured":"Mattiucci GC, Morganti AG, Cellini F, Buwenge M, Casadei R, Farioli A, et al. Prognostic impact of presurgical CA19-9 level in pancreatic adenocarcinoma: a pooled analysis. Transl Oncol. 2019;12(1):1\u20137. https:\/\/doi.org\/10.1016\/j.tranon.2018.08.017.","journal-title":"Transl Oncol"},{"issue":"6","key":"4459_CR22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","volume":"269","author":"VP Groot","year":"2019","unstructured":"Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, et al. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019;269(6):1154\u201362. https:\/\/doi.org\/10.1097\/SLA.0000000000002734.","journal-title":"Ann Surg"},{"issue":"10","key":"4459_CR23","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/bjs.5397","volume":"93","author":"CS Verbeke","year":"2006","unstructured":"Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232\u20137. https:\/\/doi.org\/10.1002\/bjs.5397.","journal-title":"Br J Surg"},{"key":"4459_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1186\/s12885-018-4901-9","volume":"18","author":"D Li","year":"2018","unstructured":"Li D, Hu B, Zhou Y, et al. Impact of tumor size on survival of patients with resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. BMC Cancer. 2018;18:985. https:\/\/doi.org\/10.1186\/s12885-018-4901-9.","journal-title":"BMC Cancer"},{"issue":"6","key":"4459_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/s1091-255x(00)80105-5","volume":"4","author":"TA Sohn","year":"2000","unstructured":"Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas \u2014 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567\u201379. https:\/\/doi.org\/10.1016\/s1091-255x(00)80105-5.","journal-title":"J Gastrointest Surg"},{"key":"4459_CR26","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1245\/s10434-025-18511-2","volume":"33","author":"S Kiritani","year":"2026","unstructured":"Kiritani S, Kawaguchi Y, Kazami Y, et al. Large resectable pancreatic cancer is associated with futile surgery: a resectable but not curable disease? Ann Surg Oncol. 2026;33:1595\u2013604. https:\/\/doi.org\/10.1245\/s10434-025-18511-2.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"4459_CR27","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/bjs.11115","volume":"106","author":"WS Tummers","year":"2019","unstructured":"Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106(8):1055\u201365. https:\/\/doi.org\/10.1002\/bjs.11115.","journal-title":"Br J Surg"},{"issue":"6","key":"4459_CR28","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1245\/s10434-008-9839-8","volume":"15","author":"I Esposito","year":"2008","unstructured":"Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651\u201360. https:\/\/doi.org\/10.1245\/s10434-008-9839-8.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4459_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/SLA.0000000000002557","volume":"269","author":"P Ghaneh","year":"2019","unstructured":"Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, et al. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019;269(3):520\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000002557.","journal-title":"Ann Surg"},{"issue":"2","key":"4459_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/path.5260","volume":"248","author":"RH Hruban","year":"2019","unstructured":"Hruban RH, Gaida MM, Thompson E, Hong SM, No\u00eb M, Brosens LA, et al. Why is pancreatic cancer so deadly? The pathologist\u2019s view. J Pathol. 2019;248(2):131\u201341. https:\/\/doi.org\/10.1002\/path.5260.","journal-title":"J Pathol"},{"issue":"1\u20132","key":"4459_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1\u20132):349\u201361. https:\/\/doi.org\/10.1016\/j.cell.2011.11.025.","journal-title":"Cell"},{"issue":"4","key":"4459_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207\u201320. https:\/\/doi.org\/10.1038\/s41575-019-0109-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4459_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/SLA.0b013e3182827a65","volume":"258","author":"M Oshima","year":"2013","unstructured":"Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S. Immunohistochemically detected expression of 3 major genes (CDKN2A\/p16, TP53, and SMAD4\/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013;258(2):336\u201346. https:\/\/doi.org\/10.1097\/SLA.0b013e3182827a65.","journal-title":"Ann Surg"},{"issue":"5","key":"4459_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.surg.2018.05.050","volume":"164","author":"S Yamada","year":"2018","unstructured":"Yamada S, Kobayashi A, Nakamori S, Baba H, Yamamoto M, Yamaue H, Fujii T. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Surgery. 2018;164(5):1049\u201356. https:\/\/doi.org\/10.1016\/j.surg.2018.05.050.","journal-title":"Surgery"},{"issue":"25","key":"4459_CR35","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","journal-title":"N Engl J Med"},{"issue":"12","key":"4459_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200\u201310. https:\/\/doi.org\/10.1056\/NEJMoa032295.","journal-title":"N Engl J Med"},{"issue":"3","key":"4459_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, et al. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(3):421\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7328.","journal-title":"JAMA Oncol"},{"issue":"16","key":"4459_CR38","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763\u201373. https:\/\/doi.org\/10.1200\/JCO.19.02274.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4459_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s002689900215","volume":"21","author":"C Sperti","year":"1997","unstructured":"Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21(2):195\u2013200. https:\/\/doi.org\/10.1007\/s002689900215.","journal-title":"World J Surg"},{"issue":"9","key":"4459_CR40","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1245\/s10434-010-1071-7","volume":"17","author":"N Wasif","year":"2010","unstructured":"Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, Tomlinson JS. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010;17(9):2312\u201320. https:\/\/doi.org\/10.1245\/s10434-010-1071-7.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4459_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439\u201357. https:\/\/doi.org\/10.6004\/jnccn.2021.0017.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"4459_CR42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00534-011-0466-6","volume":"19","author":"Y Nimura","year":"2012","unstructured":"Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012;19(3):230\u201341. https:\/\/doi.org\/10.1007\/s00534-011-0466-6.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"4459_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00000658-200301000-00011","volume":"237","author":"JE Lim","year":"2003","unstructured":"Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237(1):74\u201385. https:\/\/doi.org\/10.1097\/00000658-200301000-00011.","journal-title":"Ann Surg"},{"issue":"5","key":"4459_CR44","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/bjc.2017.479","volume":"118","author":"Y Nakano","year":"2018","unstructured":"Nakano Y, Kitago M, Matsuda S, Nakamura Y, Fujita Y, Imai S, et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Br J Cancer. 2018;118(5):662\u20139. https:\/\/doi.org\/10.1038\/bjc.2017.479.","journal-title":"Br J Cancer"},{"issue":"18","key":"4459_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"6","key":"4459_CR46","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(16)00172-8.","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04459-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04459-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04459-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:24:04Z","timestamp":1782181444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04459-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4459"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04459-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee (IEC), Minia University Faculty of Medicine Institutional Review Board (MUFMIRB) (approval number: 1118\/02\/2024), and informed consent was obtained from all patients for treatment and inclusion in the study. Procedures complied with the Declaration of Helsinki and were approved by the institutional review board.Informed consent was obtained from all patients for treatment and inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}